Track Biodesix, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Biodesix, Inc. BDSX Open Biodesix, Inc. in new tab

14.25 USD
EPS
-3.96
P/B
15.67
ROE
-316.53
Beta
0.57
Target Price
30.50 USD
Biodesix, Inc. logo

Biodesix, Inc.

🧾 Earnings Recap – Q3 2025

Biodesix reported strong third-quarter results for 2025, achieving a 20% increase in revenue and improved gross margins, while laying the groundwork for future growth in personalized diagnostics.

  • Revenue growth accelerated to 20% year-over-year, indicating robust demand for diagnostic tests.
  • Gross margins improved by 400 basis points to 81%, reflecting operational effectiveness.
  • Adjusted EBITDA enhanced by 18%, signaling progress towards profitability in Q4.
  • Tests ordered from primary care surged 75% YOY, as the company expands its market strategy to enhance lung cancer diagnostics.
  • Average revenue per test increased by 7% from Q2, supported by successful market access initiatives.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
EPS-3.96
Book Value0.90
Price to Book15.67
Debt/Equity784.17
% Insiders43.163%
Growth
Revenue Growth0.42%
Estimates
Forward P/E-64.41
Forward EPS-0.22
Target Mean Price30.50

DCF Valuation

Tweak assumptions to recompute fair value for Biodesix, Inc. (BDSX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Biodesix, Inc. Logo Biodesix, Inc. Analysis (BDSX)

United States Health Care Official Website Stock

Is Biodesix, Inc. a good investment? Biodesix, Inc. (BDSX) is currently trading at 14.25 USD. Market analysts have a consensus price target of 30.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Biodesix, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.22.

Investor FAQ

Does Biodesix, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Biodesix, Inc.?

Biodesix, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -3.96.

Company Profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Exchange Ticker
NGM (Sweden) BDSX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Sept. 15, 2025 0.050000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion